BACKGROUND: The hierarchical organization of hematopoiesis with unidirectional lineage determination has become a questionable tenet in view of the experimental evidence of reprogramming and transdifferentiation of lineage-determined cells. Clinical examples of hematopoietic lineage plasticity are rare. Here we report on a patient who presented with an acute B-lymphoblastic leukemia and developed a Langerhans' cell sarcoma 9 years later. We provide evidence that the second neoplasm is the result of transdifferentiation. DESIGN AND METHODS: B-cell acute lymphoblastic leukemia was diagnosed in an 11-year old boy in 1996. Treatment according to the ALL-BFM-1995 protocol resulted in a complete remission. Nine years later, in 2005, Langerhans' cell sarcoma was diagnosed in a supraclavicular lymph node. Despite treatment with different chemotherapy protocols the patient had progressive disease. Finally, he received an allogeneic peripheral blood stem cell transplant and achieved a continuous remission. Molecular studies of IGH- and TCRG-gene rearrangements were performed with DNA from the Langerhans' cell sarcoma and the cryopreserved cells from the acute B-lymphoblastic leukemia. The expression of PAX5 and ID2 was analyzed with real-time reverse transcriptase polymerase chain reaction. RESULTS: Identical IGH-rearrangements were demonstrated in the acute B-lymphoblastic leukemia and the Langerhans' cell sarcoma. The key factors required for B-cell and dendritic cell development, PAX5 and ID2, were differentially expressed, with a strong PAX5 signal in the acute B-lymphoblastic leukemia and only a weak expression in the Langerhans' cell sarcoma, whereas ID2 showed an opposite pattern. CONCLUSIONS: The identical IGH-rearrangement in both neoplasms indicates transdifferentiation of the acute B-lymphoblastic leukemia into a Langerhans' cell sarcoma. Loss of PAX5 and the acquisition of ID2 suggest that these key factors are involved in the transdifferentiation from a B-cell phenotype into a Langerhans'/dendritic cell phenotype. (Clinical trial registration at: Deutsches KrebsStudienRegister, http://www.studien.de, study-ID:8).
BACKGROUND: The hierarchical organization of hematopoiesis with unidirectional lineage determination has become a questionable tenet in view of the experimental evidence of reprogramming and transdifferentiation of lineage-determined cells. Clinical examples of hematopoietic lineage plasticity are rare. Here we report on a patient who presented with an acute B-lymphoblastic leukemia and developed a Langerhans' cell sarcoma 9 years later. We provide evidence that the second neoplasm is the result of transdifferentiation. DESIGN AND METHODS: B-cell acute lymphoblastic leukemia was diagnosed in an 11-year old boy in 1996. Treatment according to the ALL-BFM-1995 protocol resulted in a complete remission. Nine years later, in 2005, Langerhans' cell sarcoma was diagnosed in a supraclavicular lymph node. Despite treatment with different chemotherapy protocols the patient had progressive disease. Finally, he received an allogeneic peripheral blood stem cell transplant and achieved a continuous remission. Molecular studies of IGH- and TCRG-gene rearrangements were performed with DNA from the Langerhans' cell sarcoma and the cryopreserved cells from the acute B-lymphoblastic leukemia. The expression of PAX5 and ID2 was analyzed with real-time reverse transcriptase polymerase chain reaction. RESULTS: Identical IGH-rearrangements were demonstrated in the acute B-lymphoblastic leukemia and the Langerhans' cell sarcoma. The key factors required for B-cell and dendritic cell development, PAX5 and ID2, were differentially expressed, with a strong PAX5 signal in the acute B-lymphoblastic leukemia and only a weak expression in the Langerhans' cell sarcoma, whereas ID2 showed an opposite pattern. CONCLUSIONS: The identical IGH-rearrangement in both neoplasms indicates transdifferentiation of the acute B-lymphoblastic leukemia into a Langerhans' cell sarcoma. Loss of PAX5 and the acquisition of ID2 suggest that these key factors are involved in the transdifferentiation from a B-cell phenotype into a Langerhans'/dendritic cell phenotype. (Clinical trial registration at: Deutsches KrebsStudienRegister, http://www.studien.de, study-ID:8).
Authors: Andrew L Feldman; Caterina Minniti; Mariarita Santi; James R Downing; Mark Raffeld; Elaine S Jaffe Journal: Lancet Oncol Date: 2004-04 Impact factor: 41.316
Authors: Andrew L Feldman; Frank Berthold; Robert J Arceci; Carlos Abramowsky; Bahig M Shehata; Karen P Mann; Stephen J Lauer; Jon Pritchard; Mark Raffeld; Elaine S Jaffe Journal: Lancet Oncol Date: 2005-06 Impact factor: 41.316
Authors: Stephan Mathas; Martin Janz; Franziska Hummel; Michael Hummel; Brigitte Wollert-Wulf; Simone Lusatis; Ioannis Anagnostopoulos; Andreas Lietz; Mikael Sigvardsson; Franziska Jundt; Korinna Jöhrens; Kurt Bommert; Harald Stein; Bernd Dörken Journal: Nat Immunol Date: 2005-12-20 Impact factor: 25.606
Authors: R M Egeler; J P Neglia; M Aricò; B E Favara; A Heitger; M E Nesbit; H S Nicholson Journal: Hematol Oncol Clin North Am Date: 1998-04 Impact factor: 3.722
Authors: Christine Hacker; Ralf D Kirsch; Xin-Sheng Ju; Thomas Hieronymus; Tatjana C Gust; Christiane Kuhl; Thorsten Jorgas; Steffen M Kurz; Stefan Rose-John; Yoshifumi Yokota; Martin Zenke Journal: Nat Immunol Date: 2003-02-24 Impact factor: 25.606
Authors: A Vora; L Frost; A Goodeve; G Wilson; R M Ireland; J Lilleyman; T Eden; I Peake; S Richards Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Lucas R Massoth; Yin P Hung; Lawrence R Zukerberg; Erik A Williams; Judith A Ferry; Robert P Hasserjian; Valentina Nardi; G Petur Nielsen; Sam Sadigh; Vinayak Venkataraman; Martin Selig; Alison M Friedmann; Wesley Samore; Jonathan Keith Killian; Riza Milante; Joseph Giessinger; Kathleen Foley-Peres; Chelsea Marcus; Eric Severson; Daniel Duncan; Smruthy Sivakumar; Jeffrey S Ross; Vikram Desphande; Shakti H Ramkissoon; Jo-Anne Vergilio; Abner Louissaint Journal: Oncologist Date: 2021-05-06
Authors: A H Schmitt-Graeff; H Duerkop; B Vollmer-Kary; S Haxelmans; R Nitschke; P Fisch; U Germing; H Stein Journal: Leukemia Date: 2012-02-03 Impact factor: 11.528
Authors: Weiwei Chen; Ronald Jaffe; Linsheng Zhang; Charlie Hill; Anne Marie Block; Sheila Sait; Boer Song; Yunguang Liu; Donghong Cai Journal: N Am J Med Sci Date: 2013-06